Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients.

Leuk Lymphoma

Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilian University (LMU), Munich, Germany.

Published: February 2023

Download full-text PDF	Source
http://dx.doi.org/10.1080/10428194.2022.2148210	DOI Listing

Publication Analysis

efficacy safety

safety obinutuzumab

obinutuzumab combined

combined fludarabine

fludarabine cyclophosphamide

cyclophosphamide fcg

fcg bendamustine

bendamustine relapsed

relapsed refractory

refractory cll

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!